Key result
Achieving a systolic BP target of <140 mm Hg in hypertensive CAD patients ≥60 years old reduced the primary composite outcome compared to 140-<150 mm Hg.
Why the study?
It was unknown whether the 2014 JNC-8 systolic blood pressure target of <150 mm Hg for patients ≥60 years was optimal, particularly in coronary artery disease.
Does achieving a systolic BP target of 140 to <150 mm Hg compared to <140 mm Hg improve cardiovascular outcomes in patients ≥60 years of age with CAD?
RCT (n=8,354)
randomized
Yes
Does achieving a systolic BP target of 140 to <150 mm Hg compared to <140 mm Hg improve cardiovascular outcomes in patients ≥60 years of age with CAD?
In hypertensive patients ≥60 years of age with CAD, achieving a systolic BP target of <140 mm Hg is associated with significantly lower risks of cardiovascular mortality and stroke compared to the JNC-8 recommended target of 140 to <150 mm Hg.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The recommendation by the JNC 8 to use a less stringent goal was based on two clinical trials conducted in Japan, which failed to show that lowering systolic BP below 140 mmHg improved cardiovascular outcomes compared with a higher target goal in elderly hypertensive patients. However, the follow-up duration is relatively short, and the studies were underpowered to detect differences in cardiovascular outcomes.”
“The biggest problem this committee has is that many experts with a very significant stake in the recommendations were excluded from the process of generating the guideline. That limits buy-in from key opinion leaders, which will be needed for the uptake of this guideline into clinical practice.”
“Given the size and underlying cardiovascular risk of the population affected by the changes in the 2014 panel recommendations, close monitoring will be required to assess changes in practice patterns, blood pressure control, and – importantly – any changes in cardiovascular morbidity and mortality.”
Challenges JNC-8 lenient targets in older CAD patients; leaves open optimal systolic goal pending RCTs.
BACKGROUND: The 2014 Eighth Joint National Committee panel recommendations for management of high blood pressure (BP) recommend a systolic BP threshold for initiation of drug therapy and a therapeutic target of <150 mm Hg in those ≥60 years of age, a departure from prior recommendations of <140 mm Hg. However, it is not known whether this is an optimal choice, especially for the large population with coronary artery disease (CAD). OBJECTIVES: This study sought to evaluate optimal BP in patients ≥60 years of age. METHODS: Patients 60 years of age or older with CAD and baseline systolic BP >150 mm Hg randomized to a treatment strategy on the basis of either atenolol/hydrochlorothiazide or verapamil-SR (sustained release)/trandolapril in INVEST (INternational VErapamil SR Trandolapril STudy) were categorized into 3 groups on the basis of achieved on-treatment systolic BP: group 1, <140 mm Hg; group 2, 140 to <150 mm Hg; and group 3, ≥150 mm Hg. Primary outcome was first occurrence of all-cause death, nonfatal myocardial infarction (MI), or nonfatal stroke. Secondary outcomes were all-cause mortality, cardiovascular mortality, total MI, nonfatal MI, total stroke, nonfatal stroke, heart failure, or revascularization, tabulated separately. Outcomes for each group were compared in unadjusted and multiple propensity score-adjusted models. RESULTS: Among 8,354 patients included in this analysis with an accumulated 22,308 patient-years of follow-up, 4,787 (57%) achieved systolic BP of <140 mm Hg (group 1), 1,747 (21%) achieved systolic BP of 140 to <150 mm Hg (group 2), and 1,820 (22%) achieved systolic BP of ≥150 mm Hg (group 3). In unadjusted models, group 1 had the lowest rates of the primary outcome (9.36% vs. 12.71% vs. 21.32%; p < 0.0001), all-cause mortality (7.92% vs. 10.07% vs. 16.81%; p < 0.0001), cardiovascular mortality (3.26% vs. 4.58% vs. 7.80%; p < 0.0001), MI (1.07% vs. 1.03% vs. 2.91%; p < 0.0001), total stroke (1.19% vs. 2.63% vs. 3.85%; p <0.0001), and nonfatal stroke (0.86% vs 1.89% vs 2.86%; p<0.0001) compared with groups 2 and 3, respectively. In multiple propensity score-adjusted models, compared with the reference group of <140 mm Hg (group 1), the risk of cardiovascular mortality (adjusted hazard ratio [HR]: 1.34; 95% confidence interval [CI]: 1.01 to 1.77; p = 0.04), total stroke (adjusted HR: 1.89; 95% CI: 1.26 to 2.82; p = 0.002) and nonfatal stroke (adjusted HR: 1.70; 95% CI: 1.06 to 2.72; p = 0.03) was increased in the group with BP of 140 to <150 mm Hg, whereas the risk of primary outcome, all-cause mortality, cardiovascular mortality, total MI, nonfatal MI, total stroke, and nonfatal stroke was increased in the group with BP ≥150 mm Hg. CONCLUSIONS: In hypertensive patients with CAD who are ≥60 years of age, achieving a BP target of 140 to <150 mm Hg as recommended by the JNC-8 panel was associated with less benefit than the previously recommended target of <140 mm Hg.
No takes yet. Share an insight, caveat, or question.
Bangalore et al. (2014) conducted an RCT in Hypertension with coronary artery disease (n=8,354). Achieved systolic BP <140 mm Hg vs. Achieved systolic BP 140 to <150 mm Hg and ≥150 mm Hg was evaluated on First occurrence of all-cause death, nonfatal myocardial infarction (MI), or nonfatal stroke (p=<0.0001). Achieving a systolic BP target of <140 mm Hg in hypertensive CAD patients ≥60 years old reduced the primary composite outcome compared to 140-<150 mm Hg.
Synapse has enriched 10 related papers. Consider them for comparative context: